TY - JOUR
T1 - D-cycloserine for the treatment of ataxia in spinocerebellar degeneration
AU - Ogawa, Masafumi
AU - Shigeto, Hiroshi
AU - Yamamoto, Toshiyuki
AU - Oya, Yasushi
AU - Wada, Keiji
AU - Nishikawa, Toru
AU - Kawai, Mitsuru
PY - 2003/6/15
Y1 - 2003/6/15
N2 - We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.
AB - We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.
UR - http://www.scopus.com/inward/record.url?scp=0038639032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038639032&partnerID=8YFLogxK
U2 - 10.1016/S0022-510X(03)00009-1
DO - 10.1016/S0022-510X(03)00009-1
M3 - Article
C2 - 12736088
AN - SCOPUS:0038639032
SN - 0022-510X
VL - 210
SP - 53
EP - 56
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
IS - 1-2
ER -